Uptrend Call Working As Pacific Biosciences of California Stock Rises 28.7% (PACB)
Comtex SmarTrend(R) - Wed Dec 24, 4:58PM CST
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQ
PACB: 7.46 (+0.01)
5 Crazy Habits You Might Adopt With Low-Cost Genome Sequencing
Maxx Chatsko, The Motley Fool - Motley Fool - Sun Dec 21, 11:42AM CST
The $1,000 human genome took a giant leap closer to reality when Illumina launched the HiSeq X Ten Sequencing System in early 2014. Sequencing your genome costs over five times that amount using any other system, and had cost nearly 10 times...
PACB: 7.46 (+0.01), PFE: 31.42 (-0.03), ILMN: 186.22 (+2.72), PG: 93.14 (-0.15), NVS: 93.91 (+0.66)
How it All Plays Out -- New Research on Pacific Biosciences, Park-Ohio, Perceptron, PGT and Planar Systems
PR Newswire - Fri Dec 19, 7:10AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Pacific Biosciences (NASDAQ: PACB), Park-Ohio (NASDAQ: PKOH), Perceptron (NASDAQ: PRCP), PGT (NASDAQ: PGTI), and Planar Systems (NASDAQ: PLNR). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
PACB: 7.46 (+0.01), PGTI: 8.89 (-0.16), PRCP: 10.03 (+0.36), PKOH: 62.28 (-0.51), PLNR: 7.04 (-0.15)
Pacific Biosciences Appoints Kathy Ordonez to Board of Directors
GlobeNewswire - Thu Dec 18, 11:56AM CST
Pacific Biosciences of California, Inc., (Nasdaq
PACB: 7.46 (+0.01), DGX: 67.94 (-0.16)
Pacific Biosciences of California Shares Up 17.7% Since SmarTrend's Buy Recommendation (PACB)
Comtex SmarTrend(R) - Wed Dec 17, 11:19AM CST
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQ
PACB: 7.46 (+0.01)
Shares of PACB Up 16.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 08, 10:02AM CST
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQ
PACB: 7.46 (+0.01)
Uptrend Call Working As Pacific Biosciences of California Stock Rises 16.0% (PACB)
Comtex SmarTrend(R) - Mon Dec 01, 10:04AM CST
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQ
PACB: 7.46 (+0.01)
Pacific Biosciences Of California (PACB) Flagged As Strong On High Volume
at The Street - Fri Nov 28, 9:11AM CST
Trade-Ideas LLC identified Pacific Biosciences of California (PACB) as a strong on high relative volume candidate
PACB: 7.46 (+0.01)
Global Next Generation Sequencing Technologies Market Analysis - Trends & Forecast to 2020
M2 - Mon Nov 24, 9:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/pnm36r/global_next) has announced the addition of the "Global Next Generation Sequencing Technologies Market Analysis - Trends & Forecast to 2020" report to their offering. The global Next Generation Sequencing market is poised to grow at a CAGR of more than 20% to reach around $5.0 billion by 2020. The NGS market assessment was made based on products, technologies, end users, applications and geography. The NGS products market is further divided into instruments and reagents, services and workflow products. The instruments and consumables is the largest segment with a share of around half of the market in 2013. The fastest growing segment is the services with a highest CAGR during the forecast period. The major players are interested in services segment as it provides additional revenue for the company at the same time, increases the sales of instruments and reagents. NGS technology is segmented into targeted resequencing, whole exome sequencing, RNA sequencing, whole genome sequencing, ChIP sequencing, de novo sequencing and methyl sequencing. Among these targeted re-sequencing technology accounted for the largest share of more than 25% of the technology market in 2013 and is expected to grow at a strong CAGR during the forecast period. Whole genome sequencing is poised to grow at the highest CAGR and expected to reach a share of more than 15% of the total market by 2020. Targeted resequencing and whole genome sequencing technologies are the prospective technologies as various targeted disease based NGS assays and panels are emerging and use of personalized medicine transforms with the understanding of individual's whole genome imprint. Key Topics Covered: 1 Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Global Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Global Next Generation Sequencing Market, By End Users/Laboratories 7 Global Next Generation Sequencing Market Value And Volume Analysis, By Application 8 Geographic Analysis 9 Competitive Landscape 10 Major Player Profiles - Agilent Technologies, Inc. - Bgi (Beijing Genomics Institute) - Biomatters Ltd - Genomatix Software Gmbh - Hoffmann-La Roche Ltd. - Illumina, Inc. - Pacific Biosciences Of California Inc. - Qiagen N.V. - Strand Life Sciences Pvt. Ltd. - Thermo Fisher Scientific Inc. For more information visit http://www.researchandmarkets.com/research/pn...lobal_next
PACB: 7.46 (+0.01), A: 41.13 (-0.24), ILMN: 186.22 (+2.72), QGEN: 23.20 (+0.09)
Global Next Generation Sequencing (Genome/Exome Sequencing/DNA Sequencing) Market Forecasts and Opportunities, 2020 - Updated Report
M2 - Tue Nov 18, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/h58jql/next_generation) has announced the addition of the "Next Generation Sequencing (Genome/Exome sequencing/DNA sequencing) Global market - Forecast to 2020" report to their offering. Next generation sequencing market is one of the fastest growing segments in the genomics market with an estimated CAGR of around 17.0% in the next five years. The major factors such as rapid adoption of this technology by researchers and its usability as a substitute of microarray technology in addition to its higher throughput, increased accuracy, and affordable costs are driving the next generation sequencing market growth. However, factors such as reducing capital expenditure from academic institutions and huge dependability on grants funding from the government are hampering the next generation sequencing market growth. In addition, the analysis of large amount of data generated by sequencers, and data storage and management is posing a major challenge. The growth opportunities of this market include cloud computing, rising demand for pre-sequencing, developments in NGS fully integrated instruments and rising nanopore sequencing technology. There is a huge opportunity for this technology in the field of drug discovery, personalized medicine, agricultural and animal research. The North American region accounts for the largest share of the next generation sequencing market. The European and Asian markets are also expected to grow due to the favorable funding from the government to adopt this technology. The major factors contributing to this market growth include rising adoption by new customers, rising adoption of high-throughput sequencing platforms by government organizations such as Biotechnology and Biological Sciences Research Council (BBSRC) (U.K.) and NHGRI (National Human Genome Research Institute) (U.S.). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Next Generation Sequencing Market, By End Users/Laboratories 7 Next Generation Sequencing Market Value And Volume Analysis, By Application Area 8 Geographic Analysis 9 Company Developments 10 Major Player Profiles - Agilent Technologies, Inc. - Beijing Genome Institute - Biomatters, Ltd. - Genomatix Software Gmbh - Illumina Inc. - Life Technologies Corp. - Pacific Biosciences of California Inc. - QIAGEN N.V - Roche Holding Ltd. - Strand Life Sciences Pvt. Ltd. For more information visit http://www.researchandmarkets.com/research/h5...generation
PACB: 7.46 (+0.01), A: 41.13 (-0.24), ILMN: 186.22 (+2.72)
Pacific Biosciences of California Has Returned 17.5% Since SmarTrend Recommendation (PACB)
Comtex SmarTrend(R) - Fri Nov 14, 11:13AM CST
SmarTrend identified an Uptrend for Pacific Biosciences of California (NASDAQ
PACB: 7.46 (+0.01)
Researchers Use PacBio Sequencing to Create More Complete Human Genome Reference and Discover New Forms of Structural Variation; Paper Published in Nature
GlobeNewswire - Mon Nov 10, 10:02AM CST
Pacific Biosciences of California, Inc., (Nasdaq
PACB: 7.46 (+0.01)
Why Pacific Biosciences of California Stock Skyrocketed 34% in October
Sean Williams, The Motley Fool - Motley Fool - Tue Nov 04, 8:39AM CST
PACB data by YCharts What: Shares of Pacific Biosciences of California , a developer of complex machines capable of analyzing human DNA sequences, surged by 34% in October, based on data from S&P Capital IQ , following the company's...
PACB: 7.46 (+0.01)
Big Board Biotech Stocks in Play This Week
ACCESSWIRE - Tue Oct 28, 1:16PM CDT
Coral Gables, FL / ACCESSWIRE / October 28, 2014 / CytRx Corporation (NASDAQ: CYTR) announced that a paper, titled "A Phase 1b/2 Study of Aldoxorubicin in Patients With Soft Tissue Sarcoma," has been published online in Cancer, the prestigious, peer-reviewed journal of the American Cancer Society.
PACB: 7.46 (+0.01), CYTR: 2.58 (+0.03), KERX: 14.00 (+0.20)
New DNA Sequencing Facility Established in China Based on PacBio's SMRT Sequencing Platform
GlobeNewswire - Mon Oct 27, 4:02PM CDT
Pacific Biosciences of California, Inc., (Nasdaq
PACB: 7.46 (+0.01)